![2020 AAAAI Keynote and Plenaries 2020 AAAAI Keynote and Plenary graphic](https://education.aaaai.org/sites/default/files/styles/course_image/public/AM20%20Key%20and%20Plen%20-%20small%20for%20LMS.png?itok=vmBWA4mJ)
Plenary 4101: Rhinoviruses, Atopy and Asthma Exacerbations: Implications for Management in an Era of Biologics and Precision Medicine
This plenary reviews current paradigms of asthma exacerbation, especially the central roles of rhinoviruses and atopy, and the implications of these concepts for the evaluation of patients with asthma as well as the selection of appropriate therapies.
Lectureship | Speaker | Title |
---|---|---|
AAAAI Foundation and Allen P. Kaplan, MD FAAAAI Lectureship: Creating Knowledge for Our Future | James E. Gern, MD FAAAAI | Virus-induced Exacerbations: Epidemiology and Risk Factors |
AAAAI Foundation and I. Leonard Bernstein, MD FAAAAI Memorial Lectureship | Matthew C. Altman, MD | Mechanisms of Exacerbations: Role of Atopy and Biologic Therapies |
AAAAI Foundation and David S. Pearlman, MD FAAAAI Lectureship: Contributing to Discovery and Education | Kathleen C. Barnes, PhD FAAAAI | Genetic Susceptibility to Virus-induced Exacerbations in the Era of Precision Medicine |
Target Audience
- A/I physicians
- A/I fellows-in-training
- A/I nurses, nurse practitioners and physician assistants
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the epidemiology of virus-induced asthma exacerbations to identify those with high risk
- Explain the atopic mechanisms leading to asthma exacerbations and how new therapies reduce exacerbation risk
- Discuss genetic susceptibility to virus-induced asthma exacerbations and the potential for exacerbation prediction in precision medicine
Faculty
Matthew Altman, MD
University of Washington, Seattle, WA
Relevant relationships: None
Kathleen Barnes, PhD FAAAAI
University of Colorado Denver, Aurora, CO
Relevant relationships: None
James Gern, MD FAAAAI
University of Wisconsin, Madison, WI
Relevant relationships: None
Reviewers
Karen Gregory, DNP APRN-BC RRT AE-C
Oklahoma Allergy and Asthma Clinic, Edmond, OK
Relevant relationships: None
Kara Wada, MD
Nationwide Children’s Hospital, Columbus, OH
Relevant relationships: None
AAAAI Disclosure Policy
Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:
- Employment. Name of employer and job title.
- Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
- Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
- Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
- Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
- Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
- Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.
The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.
Accreditation Statement
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Designation Statement
The American Academy of Allergy, Asthma, & Immunology (AAAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 1.50 Contact Hours.
Credit Claiming Period
Credit claiming for this activity will expire at 11:59 pm on April 30, 2022. Requests to claim credit on or after May 1, 2022 will be denied.
AAAAI Privacy Policy
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.
Questions
Activity-related questions should be directed to cme@aaaai.org.
Available Credit
- 1.50 AttendanceAttendance credit.
- 1.50 CECE credit.
- 1.50 CMECME credit.